PARP1 and acute lymphoblastic leukemia: To our knowledge, our study is the first to show the correlation between PARP1 upregulation and the development of early relapse in pediatric ALL patients and the first to establish the need for further studies to investigate the impact of concomitant use of PARP1 inhibitors on the ALL disease recurrence after complete remission.